Ixekizumab Fab in complex with human IL-17A
Domain Annotation: SCOP2 Classification SCOP2 Database Homepage
Domain Annotation: ECOD Classification ECOD Database Homepage
| Chains | Family Name | Domain Identifier | Architecture | Possible Homology | Homology | Topology | Family | Provenance Source (Version) |
|---|---|---|---|---|---|---|---|---|
| C [auth L] | SPRY | e9sg2L1 | A: alpha arrays | X: Hypothetical protein YqbG-like | H: Hypothetical protein YqbG-like | T: alpha/beta-Hydrolases | F: SPRY | ECOD (v295.2) |
| B [auth H] | PCI | e9sg2H1 | A: alpha arrays | X: Hypothetical protein YqbG-like | H: Hypothetical protein YqbG-like | T: alpha/beta-Hydrolases | F: PCI | ECOD (v295.2) |
| A | Fusion_gly | e9sg2A1 | A: alpha arrays | X: Hypothetical protein YqbG-like | H: Hypothetical protein YqbG-like | T: alpha/beta-Hydrolases | F: Fusion_gly | ECOD (v295.2) |
SAbDab Antibody Annotation SAbDab Database Homepage
| Chain | Chain Class | Chain Subclass | Chain Type | Antigen Name(s) | Provenance Source |
|---|---|---|---|---|---|
| C [auth L] | Light Chain | IGKV2 | Kappa | interleukin-17a | SAbDab (2026-08-21) |
| B [auth H] | Heavy Chain | IGHV1 | - | interleukin-17a | SAbDab (2026-08-21) |
Thera-SAbDab Antibody Annotation Thera-SAbDab Database Homepage
| Chain | Name | Target | Provenance Source |
|---|---|---|---|
| C [auth L] | Ixekizumab | IL17A | Therapeutic SAbDab (2026-08-21) |
| B [auth H] | Ixekizumab | IL17A | Therapeutic SAbDab (2026-08-21) |
Protein Family Annotation Pfam Database Homepage
| Chains | Accession | Name | Description | Comments | Source |
|---|---|---|---|---|---|
| PF06083 | Interleukin-17 (IL17) | Interleukin-17 | - | Family |
Gene Ontology: Gene Product Annotation Gene Ontology Database Homepage
InterPro: Protein Family Classification InterPro Database Homepage
| Chains | Accession | Name | Type |
|---|---|---|---|
| IPR029034 | Cystine-knot cytokine | Homologous Superfamily | |
| IPR010345 | Interleukin-17 family | Family | |
| IPR020440 | Interleukin-17, chordata | Family |














